At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 18, 2026 at 17:31 ET
Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower R&D spending, while maintaining a $17 million cash position expected to fund operations into Q4 2026. The company emphasized strong clinical progress, including a 66% objective response rate in lymphoma and promising pancreatic cancer data, with key updates expected in Q2 2026.
- Net loss widened to $12.2 million in 2025 from $10.7 million in 2024 despite lower R&D expenses ($11.8M vs $13.5M).
- Cash, cash equivalents, and restricted cash totaled $17.0 million at year-end 2025, down from $19.2 million in 2024.
- Cash runway expected through Q4 2026 without additional grant funding.
- MT-601 showed 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with 50% complete responses.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access